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Abstract: A great amount of literature has demonstrated a connection between obesity, visceral fat and the metabolic 
disorders such as hyperglycemia, hypertension, and hyperlipidemia. Lately, there has been an increased interest in under-
standing if cancer is related to obesity and visceral fat accumulation. The prevalence of both obesity and cancer are increas-
ing and there has been keen interest in the relationship between visceral adiposity and the biology of cancers. White adipose 
tissue (WAT) provides a limitless capacity for triglyceride storage vital for survival. The concurrent rise in insulin, glucose, 
and lipids during meals stimulates triglyceride formation and storage in WAT. WAT is also recognized as an endocrine organ 
that secretes multiple cytokines such as leptin and adiponectin. In addition, leptin and adiponectin have been adipocytokines 
that attracted attention for cancer research. Thus, in this review, we will describe recent progress made in obesity, visceral 
adiposity, leptin and adiponectin in the involvement of various cancers.
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Introduction
Obesity is associated with signiﬁ  cant morbidity and mortality and is increasing in prevalence worldwide. 
Weight gain is a major predictor of the metabolic syndrome with waist circumference being a more 
sensitive indicator as it reﬂ  ects both subcutaneous and visceral adipose tissue (Matsuzawa Y, 2005). 
Associated conditions include type 2 diabetes, hypertension and dyslipidemia; a clustering of these has 
recently been termed as metabolic syndrome (Matsuzawa Y, 2005; Spiegelman BM et al. 2001; Friedman 
JM et al. 2000). Individuals affected with metabolic syndrome are at high risk factor for atherosclerosis 
and the resultant cardiovascular disease (Matsuzawa Y, 2006). The molecular mechanisms that under-
lie obesity and metabolic syndrome have not been fully elucidated, and effective therapeutic approaches 
are currently of general interest. The adipose tissue is also recognized as an endocrine organ that secretes 
multiple cytokines (Kershaw et al. 2004). Interestingly, visceral obesity and the related metabolic dis-
order have been identiﬁ  ed as risk factors for several cancers, and associated with late-stage disease and 
a poor prognosis (Carroll KK et al. 1998; Bergstrom A et al. 2001; Bray GA, 2004; Vona-Davis L et al. 
2007). Components of the metabolic syndrome, including visceral adiposity, insulin resistance, hyper-
glycemia and hyperinsulinemia have all been related to increased several cancer risk (Carroll KK et al. 
1998; Bergstrom A et al. 2001; Bray GA, 2004; Vona-Davis L et al. 2007). Obesity, type 2 diabetes and 
the metabolic syndrome also have in common an increased production of leptin (Zhang et al. 1994; 
Kershaw et al. 2004) and a decreased production of adiponectin (Scherer PE et al. 1995; Hu E et al. 
1996; Maeda K et al. 1996) by adipose tissue, with consequent elevations and reductions, respectively, 
in the circulating levels of these adipokines.
Potential roles of these adipocytokines in the regulation of cancer cell proliferation have been iden-
tiﬁ  ed (Housa D et al. 2005; Garofalo C et al. 2006). Accumulating evidences suggest that leptin and 
adiponectin may have an important role in regulating the cancer growth and proliferation (Housa D 
et al. 2005; Garofalo C et al. 2006). Leptin and adiponectin act on cancer cells directly or indirectly by 
its receptors and downstream signaling pathways. These changes in plasma leptin and adiponectin, 
acting through endocrine and paracrine mechanisms, have been associated with an increase in cancer 
risk. Several studies showed that leptin stimulates, and adiponectin inhibits, tumor cell proliferation 
and the micro vessel angiogenesis which is essential for cancer development and progression (Vona-Davis 
L et al. 2007). Clinical studies also assess leptin and adiponectin levels in relation to risk from cancer, 46
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as well as mechanistic studies to prove these 
adipocytokines role in the development of cancer. 
Circulating levels of leptin and adiponectin is cor-
related with the risk of various cancers include 
breast, endometrial, colon/gastric and prostate 
cancers (Yang WS et al. 2002; Petridou E et al. 
2003; Miyoshi Y et al. 2003). In this paper, we 
review the relationships between breast, endome-
trial, colon/gastric, prostate cancers and obesity.
Obesity and Leptin
Adipocytokine leptin, a 16-kilodaltons-peptide 
hormone, was discovered through the identiﬁ  cation 
of a mutation that produced obesity in ob/ob mice 
and involved in food intake and energy expenditure 
(Zhang Y et al. 1994). Leptin is mainly present in 
adipose tissue and blood and its receptors are 
abundant in peripheral tissues (Friedman JM, 
1998). Circulating leptin levels parallel adipose 
tissue mass and reﬂ  ect nutritional status because 
they decrease after fasting (Frederich RC et al. 
1995; Saladin PE et al. 1995). In common with 
many hormonal signals, leptin has both circadian 
rhythmicity and short-term pulsatility in circulating 
levels (Ahima RS, 2006). Leptin exerts its biologic 
actions through the activation of its cognate recep-
tors, which are encoded by the diabetes gene and 
belong to the class I cytokine receptor superfamily 
and whose signal transduction involves JAK/STAT 
pathways and adenosine monophosphate—
activated protein kinase (Lago et al. 2007).
Circulating levels of leptin and its mRNA levels 
in adipose tissue are positively correlated with 
body mass index (Maffei M et al. 1995). In fact, 
levels of leptin and its mRNA have been shown to 
be higher in obese models (Maffei M et al. 1995). 
It has been suggested that high leptin levels are 
able themselves to induce leptin resistance via an 
increase in the levels of suppressor of cytokine 
signaling 3, a blocker of leptin receptor signaling 
(Enriori et al. 2006). At any rate, the state of leptin 
resistance in common human obesity remains to 
be completely elucidated, and further studies in 
this ﬁ  eld are awaited. In anyway, these results 
indicated that a regulation of leptin and its recep-
tors might be involved in the development of 
obesity or obesity-related metabolic disorders.
Obesity and Adiponectin
Adiponectin is a 244—amino acid protein with 
structural homology to collagens VIII and X and 
complement factor C1q that is synthesized by 
adipose tissue and that increases fatty acid 
oxidation and reduces the synthesis of glucose in 
the liver and other tissues (Kadowaki and 
Yamauchi, 2005). Adiponectin has been identiﬁ  ed 
in adipose tissue as a result of screening for 
adipose-speciﬁ  c genes (Scherer PE et al. 1995; 
Hu E et al. 1996; Maeda K et al. 1996). Mouse 
cDNAs for adiponectin, termed Acrp30 (Scherer 
PE et al. 1995) and AdipoQ (Hu E et al. 1996), 
were cloned by differential display before and 
after differentiation of mouse 3T3-L1 and 3T3-
F442A cells. Adiponectin is present exclusively 
in adipose tissue and blood (Scherer PE et al. 
1995; Hu E et al. 1996; Maeda K et al. 1996), and 
its receptors are abundant in peripheral tissues 
(Yamauchi T et al. 2003).
Circulating levels of adiponectin and its mRNA 
levels in adipose tissue are negatively correlated 
with body mass index (Arita Y et al. 1999). In fact, 
levels of adiponectin and its mRNA have been 
shown to be lower in obesity (Arita Y et al. 1999). 
In addition, patients with type 2 diabetes also 
showed lower levels of plasma adiponectin, 
indicating the involvement of this adipocytokine 
in glucose metabolism (Hotta K et al. 2000). 
Adiponectin treatment has been shown to improve 
insulin resistance (Berg H et al. 2001; Yamauchi T 
et al. 2001). Furthermore, adiponectin treatment 
has been shown to increase free fatty acid beta-
oxidation via AMPK—dependent pathway 
(Yamauchi T et al. 2002), and adiponectin-
deficient mice developed insulin resistance 
(Kubota N et al. 2002; Maeda N et al. 2002). 
Adiponectin interacts with two receptors (Adi-
poR1 and AdipoR2) (Yamauchi T et al. 2003; 
Kadowaki T et al. 2005). AdipoR1 is expressed 
mainly in skeletal muscles while AdipoR2 is 
expressed mainly in the liver. Both AdipoR1 and 
AdipoR2 contain—G-protein coupled recep-
tors—seven transmembrane domains (Yamauchi 
T et al. 2003; Kadowaki T et al. 2006). These ﬁ  nd-
ings suggest that a regulation of adiponectin and its 
receptors may be involved in the development of 
obesity or obesity-related metabolic disorders as 
well as leptin.
Breast Cancer, Leptin
and Adiponectin
Adipocytokine leptin is associated with various 
cancers including breast, endometrial, gastric, and 47
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prostate cancers (Tables 1, 2). Especially, circulating 
leptin concentrations are correlated with the inci-
dence of breast carcinoma. Expression of leptin 
and its receptors were found in normal mammary 
tissue, as well as breast cancer tissue (O'Brien 
et al. 1999; Ishikawa et al. 2004). In addition, 
both leptin and its receptors have been elevated 
in cancer tissue compared with normal tissue 
(Ishikawa et al. 2004). Leptin induced the breast 
cancer carcinogenesis and invasion. The biologi-
cal effect of leptin on breast cancer came from 
the ﬁ  ndings of leptin-induced proliferation of 
breast cancer cells (Hu et al. 2002; Yin et al. 
2004). Leptin exerts its growth effect on breast 
cancer cell lines through activation of multiple 
signaling cascades, including the JAK/STAT, 
ERK1/2, PKC- alpha and PPAR signaling 
pathways (Hu et al. 2002; Okumura et al. 2002; 
Garofalo et al. 2004; Yin et al. 2004). Leptin may 
inﬂ  uence breast cancer development in relation 
to ER status (Ray A et al. 2007). Gonzalez RR 
et al. demonstrated that the inhibition of leptin 
signaling could serve as a potential adjuvant 
therapy for treatment of breast cancer and provide 
a target for the designing strategies to pre-
vent mammary tumor development (Gonzalez 
RR et al. 2007). Several clinical studies also 
demonstrated the relationship between obesity, 
leptin and breast cancer. However, the clinical 
studies on circulating leptin levels and breast 
cancer are not conclusive. Previous studies 
demonstrated that high body mass index and 
central obesity are associated with an increased 
risk of breast cancer (Chang et al.1998; Harvie 
Table 1. Effect or association of leptin on breast and endometrial cancer.
Type of cancer  Effect or association  References 
Breast  Increased cell growth and proliferation  (Hu et al. 2002; Yin et al. 2004) 
Activation of JAK/STAT
and ERK 1/2 signaling
(Hu et al. 2002; Yin et al. 2004)
Relation to ER status  (Ray et al. 2007)
Potential adjuvant therapy  (Gonzalez et al. 2007) 
Positive association with breast cancer  (Tessitore et al. 2000) 
Lack of association with cancer risk  (Mantzoros et al.1999; Sauter et al. 2004) 
Negative association with cancer risk  (Petridou et al. 2000) 
Endometrium  Activation of the JAK/STAT signaling  (Sharma et al. 2006) 
Autocrine effect to stimulate cancer  (Koda et al. 2006) 
Positive association
with endometrial cancer 
(Petridou et al. 2002) 
Table 2. Effect or association of leptin on colonal and prostate cancer. 
Type of cancer  Effect or association  References 
Colon  Promoted invasiveness by the
PI-3K, Rhoand rac signaling 
(Attoub et al. 2000) 
Increased colonic cell growth  (Hardwick et al. 2001) 
Positive association with cancer risk  (Stattin et al. 2003) 
Lack of association with cancer risk  (Tessitore et al. 2000) 
Prostate  Increased cell proliferation
and suppression of apoptosis 
(Somasunder et al. 2004) 
Positive association with cancer risk  (Stattin et al. 2001; Saglam et al. 2003) 
  Lack of association with cancer risk  (Lagiou et al.1998; Stattin et al. 2003) 48
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et al. 2003). Circulating leptin and leptin mRNA 
expression levels were both elevated in breast 
cancer patients and increase in leptin mRNA 
expression levels (Tessitore et al. 2000). Contrary, 
in breast cancer in situ, leptin does not appear to 
increase the risk of pre-menopausal cancer 
(Mantzoros et al. 1999). Sauter et al. also indi-
cated serum levels of leptin were not associated 
with premenopausal or postmenopausal breast 
cancer (Sauter et al. 2004). Other studies 
demonstrated leptin are inversely related to breast 
cancer risk among premenopausal women (Petri-
dou et al. 2000).
Low serum adiponectin is associated with high 
incidence of obesity-related cancer diseases, 
including breast cancers (Table 3.). Breast cancer 
cells expressed AdipoR1 and R2, but not adipo-
nectin (Takahata C et al. 2007; Kornar A et al. 
2007). Expression of AdipoR1, but not AdipoR2, 
was higher in breast tumor tissue than control tis-
sues (Kornar A et al. 2007). Prolonged adiponectin 
treatment caused cell growth arrest and apoptosis 
of MCF7 and MDA-MB-231cell (Kang JH et al, 
2005; Dieudonne et al, 2006). Exposure of T47D 
cells to high-molecular-weight adiponectin sig-
niﬁ  cantly inhibited the percentage of viable cells 
and proliferation (Kornar A et al. 2007). These 
effects were associated with activation of ERK1/2 
but not AMP-activated protein kinase or p38MAPK 
(Kornar A et al. 2007). It is indicated that adipo-
nectin can directly control cancer cell growth. 
Clinical data from different ethnic populations 
indicate that low adiponectin plasma level is an 
independent risk factor for breast cancer disease. 
An inverse relationship of circulating adiponectin 
levels and breast cancer risk in postmenopausal 
women was observed independently of possible 
effects of IGF-1, leptin, and BMI (Mantzoros et al. 
2004). Miyoshi et al. also demonstrated that an 
association of low serum adiponectin levels with 
increased risk of breast cancer in both 
postmenopausal and premenopausal women 
(Miyoshi et al. 2003). Korner A et al. described 
that women with the lowest adiponectin levels 
had an increased risk of breast cancer (Korner A 
et al. 2007).
Endometrial Cancer, Leptin
and Adiponectin
Similar to breast cancer, leptin and adiponectin 
are associated with endometrial cancer. Leptin 
receptor mRNA and its proteins are expressed in 
the endometrium (Koda et al. 2007). The effect of 
leptin on endometrial cancer carcinogenesis is due 
to leptin-induced cell growth of endometrial can-
cer. Leptin promotes endometrial cancer growth 
and invasiveness and implicate the JAK/STAT and 
AKT pathways (Sharma D et al. 2006). Leptin 
could exert autocrine effect to stimulate endome-
trial cancer progression (Koda et al. 2007). The 
relationship between obesity, leptin and endome-
trial cancer risk have been observed in clinical 
studies. Obesity is strongly related to endometrial 
cancer (Calle EE and Thun MJ, 2004). A linear 
increase in the risk of endometrial cancer with 
increasing body weight has been observed (Calle 
EE et al. 2003). Circulating leptin levels were 
positively associated with endometrial cancer 
(Petridou et al. 2002). Similarly, Yuan et al. 
showed that circulating leptin was higher in endo-
metrial cancer patients, however this association 
Table 3. Effect or association of adiponectin on cancer.
Type of cancer  Effect or association References
Breast  Regulate cell growth,
and proliferative response 
(Kang et al. 2005; Dieudonne et al. 2006;
Korner et al. 2007). 
Inverse relationship of adiponectin
levels and the cancer risk 
(Mantrozos et al. 2004; Miyoshi et al. 2003;
Korner et al. 2007) 
Endometrial  Regulate cell growth,
and proliferative response 
(Cong et al. 2007) 
Inverse relationship of adiponectin
levels and the cancer risk 
(Petridou et al. 2003; Dal Maso et al. 2004;
Cust et al. 2007) 
Colon  Inverse relationship  (Ferroni et al. 2007) 
Gastric  Regulate proliferative response  (Ishikawa et al. 2007) 
Prostate  Regulate cell growth  (Bub et al. 2006; Barb et al. 2007) 49
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was not observed after BMI normalization (Yuan 
et al. 2004).
Adiponectin receptors were expressed in the 
human endometrium (Takemura Y et al. 2006). 
Cong et al. demonstrated that adiponectin leads 
to suppression of cell proliferation in human 
endometrial carcinoma cell, which is primarily 
due to the signiﬁ  cant increase of cell populations 
at G (1)/G (0)-phase and to the induction of 
apoptosis (Cong et al. 2007). It is suggested that 
adiponectin exerts direct anti-proliferative effects 
on the cells by inducing cell cycle arrest and 
apoptosis (Cong et al. 2007). An inverse asso-
ciation of endometrial cancer in women and 
adiponectin had independent roles in promoting 
endometrial cancer (Petridou et al. 2003; Dal 
Maso et al. 2004). High circulating adiponectin 
levels are associated with reduced endometrial 
cancer risk, largely independent of other obesity-
related risk factors (Cust AE et al. 2007). The 
association remained statistically signiﬁ  cant after 
separate adjustment for other obesity-related 
physiological risk factors such as C-peptide (Cust 
AE et al. 2007).
Colon/gastric Cancer, Leptin
and Adiponectin
Colon cancer is the common cause of cancer death 
and the rapid increase in the cancer incidence in 
several populations suggest environmental factors, 
including high-fat diet and obesity (Frezza EE et al. 
2006). High fat diet that increase circulating leptin 
promote carcinogenesis by stimulating colon cell 
proliferation (Liu Z et al. 2001). Leptin receptors 
were expressed in both tumor tissue and colon 
cancer cell line HT29 (Hardwick JC et al. 2001). 
Leptin induced cell proliferation and p42/44 
MAPK phosphorylation (Hardwick JC et al. 2001). 
Previous study showed that leptin promotes 
invasiveness of colonic epithelial cells via phos-
phoinositide 3-kinase-, rho-, and rac-dependent 
signaling pathways (Attoub et al. 2000). Leptin 
was shown to work as a mitogen for intestinal 
epithelial cells and also decreased apoptotic cell 
death in a cancer cell line (Rouet-Benzineb P et al. 
2004). Leptin has also been shown to enhance 
the development of adenomatous lesions in 
genetically obese mice (Hirose Y et al. 2004). In 
contrast, a study showed that leptin did not pro-
mote the growth of colon cancer xenografts in 
nude mice (Aparicio T et al. 2005). Obesity has 
been associated with higher risk of colorectal 
cancer and adenomas in men and women (Calle 
and Thun, 2004; Giovannucci et al. 1995). The link 
between colorectal cancer and obesity is more 
signiﬁ  cant in men than in women (Terry et al. 2001, 
2002; Stattin et al. 2003). On the other hand, no 
difference was found between serum leptin levels 
in cancer patients and controls (Tessitore et al. 
2000). Other authors demonstrated that circulating 
leptin levels in patients with colon cancer were 
signiﬁ  cantly decreased (Arpaci et al. 2002). In the 
study, leptin levels were lower in colon cancer 
patients despite lack of weight loss and BMI mea-
surements comparable to that of control subjects. 
Thus, further studies would be necessary for 
clarify the relationship leptin and colon cancer in 
clinical study. Adiponectin potently induced apop-
tosis and inhibited the proliferation of AZ521 cells 
(Ishikawa et al. 2007). Down-regulation of either 
AdipoR1 or AdipoR2 by speciﬁ  c siRNA signiﬁ  -
cantly suppressed the growth inhibitory effects of 
adiponectin in the cell line. In addition, adiponectin 
negatively regulates the progression of gastric 
cancer cells possibly through both AdipoR1 and 
AdipoR2. Circulating adiponectin levels are 
inversely correlated with the risk of colorectal 
cancer (Ferroni et al. 2007). The median adiponec-
tin levels were lower in colorectal cancer patients 
than controls (Ferroni et al. 2007). Moreover, 
median adiponectin concentration gradually 
decreased with increase in tumor stage. Thus, low 
serum adiponectin might represent an adjunctive 
tool in risk prediction for colorectal cancer 
recurrence.
Prostate Cancer, Leptin
and Adiponectin
Although several data appeared conﬂ  icting, recent 
studies have clarified the association between 
leptin and prostate cancer. Leptin induced in vitro 
proliferation and inhibited apoptosis of prostate 
cell lines Somasundar et al. (2004). The effects of 
leptin were mediated through activation of a short 
form of leptin receptor. In addition, the activation 
of PI3 and MAPK pathway were shown to be 
involved in the process of leptin-induced 
proliferation. Clinical studies focused on 
comparison of serum leptin levels in benign 
prostatic hyperplasia, prostate cancer and control 
healthy subjects (Schuurman et al. 2000; Jonsson 
et al. 2003; Hubbard et al. 2004). The studies on 50
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circulating leptin levels and prostate cancer are not 
conclusive. Moderately elevated plasma leptin 
concentrations are associated with later development 
of prostate cancer (Stattin et al. 2001; Saglam et al. 
2003). Single nucleotide polymorphism G/A in 
region—2548 bp of leptin gene was associated 
with the risk of prostate cancer development and 
more advanced stage in already developed cancer 
(Ribeiro et al. 2004). By contrast, the association 
between leptin levels and prostate cancer risk was 
not signiﬁ  cant (Lagiou P et al. 1998; Stattin et al. 
2003). As well as the above cancers, further stud-
ies would be necessary for clarify the relationship 
leptin and prostate cancer in clinical study. In 
prostate cancer cells, adiponectin inhibited the cell 
growth (Bub JD et al. 2006). Adiponectin can 
activate AMPK in cell, suggesting that adiponectin 
may suppress tumor development through AMPK 
activation and subsequent inhibition of mammalian 
target of rapamycin (mTOR) (Barb D et al. 2007). 
This adiponectin stimulation of mTOR was medi-
ated through phosphatidylinositol 3-kinase and Akt 
activation (Barb D et al. 2007). These results show 
that adiponectin can activate both AMPK and PI3 
kinase/Akt pathways, and that cell type-speciﬁ  c 
factors may determine which of these pathways 
will have the dominant effect on mTOR.
Conclusions
It has been described that obesity, leptin and 
adiponectin are related with the risk of some types 
of cancer such as that of the breast, endometrium, 
colon and prostate. In these cancer cell lines, 
adipocytokine leptin stimulates cell growth, 
proliferation and invasion of the cells in vitro. 
Contrary, adiponectin down-regulates the cancer 
cell growth and proliferation. Evidence suggests a 
role for obesity, leptin and adiponectin in regulat-
ing the progression of established cancer. Emerging 
data suggest obesity increases the risk of aggressive 
cancer, while simultaneously decreasing the risk 
of more indolent disease. This is likely driven by 
both “biological” and “nonbiological” causes. 
Despite several biological mechanisms that 
potentially link obesity to cancer, the effects of 
obesity on the subsequent effects on the detection 
of cancer, are not consistent according to the 
previous literature. Additionally, the epidemiologic 
data for the incidence of cancer in obese and non-
obese populations are conﬂ  icting. It is difﬁ  cult to 
determine whether oncologic and functional 
outcomes in obese patients differ substantially 
from those in non-obese patients. Hopefully, the 
increasing focus on these health problems might 
further elucidate their complex relationship in the 
future.
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